fashion -WSS

fashion

author：hotspot 2025-09-04 22:14:51 - browse：782

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： New chart reveals military’s vast involvement in Operation Warp Speed

explore

WSS

Testing for cancer recurrence creates a new limbo for patients

Why Sanofi got shellacked over its spinoff

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

'The View' co

What is the Turing Test that determines if computers can think?

Prosecutors say FTX founder Sam Bankman

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

First Opinion Podcast: How to protect health care in times of war

Sports medicine is finally prioritizing gender equality

Diversifying clinical trials isn't enough to close racial gaps: study

Moonlake's readout produced a cash windfall. Risks remain

'The View' co

What does generative AI mean for health care? We asked experts

Hospitals warn Medicare's drug payment fix is ‘unlawful’

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why the advice to take all your antibiotics may be wrong

knowledge

Biden's order seeks to regulate AI risk without stifling innovation

Maker of FluMist seeks to allow at

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Readout Newsletter: What happened with Sarepta's Duchenne data

Chimpanzees, like humans and whales, get menopause: Study

It's time to take a new tack for treating Alzheimer's

hotspot

hotspot

explore

Wikipedia